Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Most of the included studies compared the glucagon-like peptide-1 (GLP-1) receptor agonists with insulin and metformin
This reprogramming not only supplies energy and biosynthetic precursors necessary for engulfment but also critically influences the functional phenotype of phagocytes through complex molecular networks
The differences seen by income groups may be influenced by both the increased use of GLP-1 RAs during the study period (Rodriguez et al., 2023) and the change in clinical guidelines during the period (Summary of Revisions, 2020)
We highlight how multireceptor agonists and oral GLP-1based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options
US$ 23.64
US$ 26.92
US$ 29.39
US$ 21.76
US$ 22.96
US$ 20.99
